JP2021513866A5 - - Google Patents
Info
- Publication number
- JP2021513866A5 JP2021513866A5 JP2020544787A JP2020544787A JP2021513866A5 JP 2021513866 A5 JP2021513866 A5 JP 2021513866A5 JP 2020544787 A JP2020544787 A JP 2020544787A JP 2020544787 A JP2020544787 A JP 2020544787A JP 2021513866 A5 JP2021513866 A5 JP 2021513866A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- ats
- ube3a
- target nucleotide
- guide rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635815P | 2018-02-27 | 2018-02-27 | |
| US62/635,815 | 2018-02-27 | ||
| PCT/US2019/019789 WO2019168950A1 (en) | 2018-02-27 | 2019-02-27 | Methods and compositions for treating angelman syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513866A JP2021513866A (ja) | 2021-06-03 |
| JP2021513866A5 true JP2021513866A5 (https=) | 2022-03-09 |
Family
ID=67805564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544787A Pending JP2021513866A (ja) | 2018-02-27 | 2019-02-27 | アンジェルマン症候群を処置する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210054370A1 (https=) |
| EP (1) | EP3758714A4 (https=) |
| JP (1) | JP2021513866A (https=) |
| CN (1) | CN111770758A (https=) |
| CA (1) | CA3091912A1 (https=) |
| WO (1) | WO2019168950A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102922694B1 (ko) | 2018-04-19 | 2026-02-03 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 유전자 편집을 위한 조성물 및 방법 |
| EP3980533A1 (en) | 2019-06-07 | 2022-04-13 | Scribe Therapeutics Inc. | Engineered casx systems |
| US20230042176A1 (en) * | 2019-12-18 | 2023-02-09 | National University Of Singapore | Method for treating angelman syndrome and related disorders |
| JP2023524247A (ja) * | 2020-04-28 | 2023-06-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アンジェルマン症候群の治療のための組成物及びその使用 |
| KR20230128289A (ko) | 2020-12-03 | 2023-09-04 | 스크라이브 테라퓨틱스 인크. | 조작된 클래스 2 유형 v crispr 시스템 |
| WO2023168000A1 (en) * | 2022-03-03 | 2023-09-07 | The Regents Of The University Of California | Compositions and methods for treatment of angelman syndrome |
| WO2023184108A1 (en) * | 2022-03-28 | 2023-10-05 | Huigene Therapeutics Co., Ltd. | Crispr-cas13 system for treating ube3a-associated diseases |
| CN116004788B (zh) * | 2022-08-01 | 2024-05-31 | 湖南家辉生物技术有限公司 | 一种Angelman综合症致病基因UBE3A突变位点的应用及其诊断试剂 |
| WO2026006542A2 (en) * | 2024-06-26 | 2026-01-02 | Yale University | Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome |
| CN119177283B (zh) * | 2024-11-25 | 2025-03-07 | 嘉检(广州)生物工程技术有限公司 | 用于pws/as快速诊断的引物组、试剂盒及系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014004572A2 (en) * | 2012-06-25 | 2014-01-03 | Isis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
| EP3031921B1 (en) * | 2012-12-12 | 2025-03-12 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP3183358B1 (en) * | 2014-08-19 | 2020-10-07 | President and Fellows of Harvard College | Rna-guided systems for probing and mapping of nucleic acids |
| US10400243B2 (en) * | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
| WO2017048466A1 (en) * | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Compositions and methods for delivering biotherapeutics |
| US20190127713A1 (en) * | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| WO2019084140A1 (en) * | 2017-10-24 | 2019-05-02 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES |
| KR102723989B1 (ko) * | 2017-12-01 | 2024-11-01 | 더 텍사스 에이 & 엠 유니버시티 시스템 | 엔젤만 증후군 안티센스 치료 |
| EP3720508A4 (en) * | 2017-12-08 | 2021-09-01 | University of Connecticut | COMPOSITIONS AND METHODS FOR TREATMENT OF GENOMIC FOOTPRINT DISORDERS |
-
2019
- 2019-02-27 WO PCT/US2019/019789 patent/WO2019168950A1/en not_active Ceased
- 2019-02-27 EP EP19761013.2A patent/EP3758714A4/en not_active Withdrawn
- 2019-02-27 US US16/976,386 patent/US20210054370A1/en not_active Abandoned
- 2019-02-27 JP JP2020544787A patent/JP2021513866A/ja active Pending
- 2019-02-27 CN CN201980015559.2A patent/CN111770758A/zh active Pending
- 2019-02-27 CA CA3091912A patent/CA3091912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513866A5 (https=) | ||
| Kaminski et al. | Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study | |
| Kay | State-of-the-art gene-based therapies: the road ahead | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| Morgan et al. | Sequence conservation and differential expression of Marek's disease virus microRNAs | |
| JP2023527354A5 (https=) | ||
| RU2018124657A (ru) | Способы редактирования генов и композиции для устранения риска активации вируса jc и пмл (прогрессирующая мультифокальная лейкоэнцефалопатия) во время иммуносупрессивной терапии | |
| JP2021536244A5 (https=) | ||
| JP2020508685A5 (https=) | ||
| Hüser et al. | Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing | |
| JP2019519218A5 (https=) | ||
| JP2016537341A5 (https=) | ||
| JP2019513393A5 (https=) | ||
| JP2017079759A5 (https=) | ||
| WO2018022480A1 (en) | Treating cancer | |
| JP2023055809A5 (https=) | ||
| JP2005521393A5 (https=) | ||
| CN112469421A (zh) | 减少剪接病和治疗rna显性疾病的组合物和方法 | |
| JP2021522858A5 (https=) | ||
| RU2019100525A (ru) | Векторная система на основе аденоассоциированного вируса | |
| JP2024107295A5 (https=) | ||
| JP2019523648A5 (https=) | ||
| MX2022004352A (es) | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c. | |
| JP2019509756A5 (https=) | ||
| Imbert et al. | Lowering mutant huntingtin using tricyclo-DNA antisense oligonucleotides as a therapeutic approach for Huntington's disease |